Investment Rating - The investment rating for Kelun Pharmaceutical is Neutral, with a target price raised to RMB 41 from RMB 39, indicating a potential upside of 31.5% from the current price of RMB 31.18 [6][4][3]. Core Insights - Kelun Pharmaceutical reported a revenue of RMB 11.827 billion for the first half of 2024, a year-on-year increase of 9.5%, which aligns with the forecast [1]. - The company's net profit attributable to shareholders was RMB 1.8 billion, a 28% increase year-on-year, but below expectations [1]. - The actual tax rate for the first half of 2024 was estimated at 36%, higher than anticipated due to the expiration of previous tax incentives [1]. - The company is a leading player in the infusion products market and a significant entity in the APIs and generic drugs sector, with growth driven by the ramp-up of innovative drugs [3]. Summary by Sections Financial Performance - Revenue for 2024 is projected at RMB 23.89 billion, with net profit estimates of RMB 3.136 billion, reflecting a 3% increase from previous estimates [2]. - The earnings per share (EPS) for 2024 is forecasted at RMB 2.20, up 2.8% from earlier predictions [2]. Valuation Methodology - The target price of RMB 41 is derived using a sum-of-the-parts valuation method, applying a 16.6x P/E ratio for the infusion and generic drug business, consistent with global peers [4]. - The valuation also considers the market value of investments in subsidiaries and a discounted cash flow approach for the innovative drug segment [4]. Market Position and Growth Drivers - Kelun Pharmaceutical's current implied P/E ratio is 15.8x, which is relatively reasonable compared to the industry average of 16.6x [3]. - Key growth drivers include fluctuations in API prices, the speed of innovative drug launches, and updates on centralized procurement policies [3].

Investment Rating - The report maintains a Neutral rating for the company [1][3][7]. Core Insights - The company reported a revenue of RMB 27.91 billion and a net profit of RMB 4.37 billion for the first half of 2024, reflecting a year-on-year growth of 9% and 2% respectively, which aligns with forecasts [1][3]. - The second quarter of 2024 saw revenue and net profit of RMB 15.99 billion and RMB 3.04 billion, showing a year-on-year increase of 11% and 7% respectively [1][3]. - The life sciences and industrial testing segments experienced steady growth, while the pharmaceutical and semiconductor sectors faced challenges [1][3][7]. - The gross margin improved by 2 percentage points in the second quarter, attributed to efficiency gains from digitalization and the expansion of higher-margin chemical testing services [1][3]. - The company anticipates a slight improvement in performance for the second half of 2024, driven by accelerated growth in traditional food and environmental testing [1][3]. Summary by Relevant Sections Financial Performance - For the first half of 2024, the company achieved a revenue of RMB 27.91 billion and a net profit of RMB 4.37 billion, with respective year-on-year growth rates of 9% and 2% [1]. - The second quarter results were RMB 15.99 billion in revenue and RMB 3.04 billion in net profit, with year-on-year growth of 11% and 7% [1][3]. Segment Performance - Life Sciences: Revenue grew by 22% year-on-year in the first half and 23% in the second quarter, driven by traditional food and environmental testing [1][3]. - Industrial Testing: Revenue increased by 14% year-on-year in the first half and 8% in the second quarter, supported by digitalization and carbon emission certification [3]. - Pharmaceutical Sector: Revenue declined by 34% year-on-year in the first half and 15% in the second quarter, although the decline rate narrowed in the second quarter [3]. Future Outlook - The company expects a decrease in revenue contribution from soil testing in the second half, but anticipates accelerated growth in traditional food and environmental testing [1][3]. - The management forecasts a stable growth of approximately 20% in the traditional consumer testing segment and a recovery in semiconductor testing [2][3]. Valuation - The report adjusts the earnings per share forecast for 2024-2027 upwards by 1% to 2%, reflecting the company's performance and outlook, with a 12-month target price raised to RMB 15.0, based on a 21x P/E ratio for 2025 [3][4].

Investment Rating - The report provides a neutral investment rating for the covered companies, indicating a cautious outlook on the real estate sector in China [25]. Core Insights - The report highlights a significant decline in new housing sales, with first-hand housing sales down 23% year-on-year and second-hand housing sales showing a slight increase of 3% year-on-year [16][19]. - The report notes that the average sales area of first-hand housing has decreased by 33% year-to-date compared to the previous year, with a notable decline in sales across various city tiers [13][14]. - Inventory levels have slightly decreased by 0.1% compared to the previous month, with a total inventory month count of 26.7 months, indicating a tightening market [19][20]. Summary by Sections Sales Performance - First-hand housing sales area decreased by 23% month-on-month and year-on-year, with second-tier cities showing a 7% decline [8][10]. - Year-to-date, first-hand housing sales area has averaged a 33% decline compared to the previous year, while second-hand housing sales have decreased by 3% [13][16]. Market Trends - The report indicates that the sales volume of top 100 developers may decline by 8% year-on-year, a significant improvement from the previous month's 40% decline [16]. - The report also mentions that the expectation of price increases among sellers is weakening, despite a slight increase in second-hand housing sales [16][19]. Construction and Inventory - New construction area is expected to decline by 30% to 35% year-on-year for July and August, reflecting ongoing challenges in the market [3][22]. - The report tracks that the completion area is projected to decrease by nearly 20% year-on-year, with an overall expected increase of 3% for the year [22][23]. Valuation - The report notes that the current price-to-book ratios for both mainland and overseas listed developers are at historical lows, with discounts of 56% and 40% to expected net asset values, respectively [25][26].

Investment Rating - The report maintains a "Buy" rating for Zhejiang Dingli Co Ltd. (603338.SS) with an upside potential of 56.2% to a target price of Rmb51.85 [1][3][21]. Core Insights - The investment thesis for Zhejiang Dingli is based on several factors including the accelerating adoption of aerial working platforms (AWPs) in China, a significant under-penetrated market, driven by rising labor costs, a construction worker shortage, and increasing safety awareness [21]. - The company is expected to benefit from a product mix upgrade towards higher-ASP and higher-barrier-to-entry boom lifts, where it has established a substantial technology gap compared to domestic peers [21]. - Despite the challenges posed by US-China trade tensions and anti-dumping duties, Dingli's competitiveness is expected to grow due to product differentiation, particularly in electrified boom technology [21]. Financial Projections - Revenue projections for Zhejiang Dingli are as follows: Rmb6,312.0 million for 2023, Rmb7,435.9 million for 2024E, Rmb8,421.7 million for 2025E, and Rmb9,548.8 million for 2026E [3][21]. - EBITDA is projected to grow from Rmb1,912.8 million in 2023 to Rmb3,198.1 million by 2026E [3][21]. - The report anticipates a core EPS CAGR of +22% from 2023 to 2025E, with EPS expected to be Rmb3.69 in 2023, increasing to Rmb5.47 by 2026E [3][21]. Market Context - The report highlights a normalization in the rental market, with softened fleet utilization and cautious demand from rental companies, indicating a potential peak in the cycle [1][10]. - The AWP segment in North America saw a growth of 6-7% year-over-year, but there were declines in other regions, particularly Europe [14][16]. - The overall market dynamics suggest a cautious outlook for the construction sector, with uncertainties related to interest rates impacting demand [11][21]. Valuation Metrics - The target price of Rmb81.0 is based on a 16.5X 2024E DACF, reflecting a ~45% discount to its long-term historical average [22]. - The report projects a P/E ratio of 20.2X for 2024E and 16.8X for 2025E, justified by the expected growth in core EPS [22]. Competitive Landscape - The report notes that Zhejiang Dingli is one of the largest suppliers of AWPs in China, with significant growth potential in both domestic and international markets [21]. - The company faces competition from both local and international players, but its focus on product differentiation and technology leadership is expected to provide a competitive edge [21].

Investment Rating - The report maintains a "Buy" rating for both Yue Yuen and Pou Sheng, with a 12-month target price of HK$17.2 for Yue Yuen and HK$1.00 for Pou Sheng [20][23]. Core Insights - Yue Yuen's OEM business has shown sequential order improvement, with management raising full-year order volume growth guidance to low double digits year-over-year, indicating better visibility on second-half orders [3][12]. - Pou Sheng's retail business faces challenges due to weak consumption power in China, but effective margin control and cost optimization strategies are expected to support stability [5][8]. Summary by Sections OEM Business Overview - Order Outlook: Full-year order volume growth guidance raised to low double digits year-over-year from mid-single to high-single digits, with improved visibility for second-half orders [3][12]. - Margin Expectations: Gross profit margin (GPM) in Q2 was 18%, below expectations, but management anticipates stability or a marginal increase in GPM for the second half [14]. - Capacity Expansion: Ongoing capacity expansion in Bangladesh, Indonesia, and Cambodia, with plans for a new production base in India [15][16]. Retail Business Overview (Pou Sheng) - Sales Performance: Sales declined by 11% year-over-year in July, with management expecting similar trends to continue in the second half [5][7]. - Margin Management: Despite sales pressure, Pou Sheng achieved a gross profit margin of 34.2% in Q2, with expectations for stabilization in the second half [8][10]. - Cost Control Initiatives: Continuous efforts in optimizing SG&A costs have led to savings, including adjustments in labor and rental costs [5][8]. Earnings Revisions - For Pou Sheng, net income estimates for 2024 have been revised up by 9%, while estimates for 2025-2026 have been increased by 0%-2% due to better gross profit margin improvement and operational efficiency [6][19]. - For Yue Yuen, slight adjustments to gross profit margin forecasts have been made, reflecting recent results and new factory ramp-up [6][17]. Strategic Initiatives - Pou Sheng is enhancing its digitalization efforts and multi-channel strategies to counteract offline sales softness, with a focus on improving operational efficiency in high-tier cities [9][10]. - New brand collaborations and outlet-formatted stores are being pursued to drive growth and improve sales performance [10][11].

14 August 2024 | 6:40AM HKT Tencent Music Entertainment Group (tme) Buy Earnings Review: 2024 in-line: Shifting gear to ARPPU over subs, expectation reset but still long runway of growth; Buy TMEUpside: 27.7%12m Price Target: $14.20Price: $11.12 1698.HK12m Price Target: HK$55.10Price: HK$53.50Upside: 3.0% TME delivered in-line 2Q24 results (see our note) yet produced a mixed outlook over 2H24-2025 including: 1) A shift in gear of growth drivers may raise concerns for some investors on multiple contraction, ...

Investment Rating - Maintain Buy rating on Wanhua Chemical Group (600309 SS) with a revised 12-month target price of Rmb106 0 per share, up from Rmb103 0 [2][5] Core Thesis - The polyurethane cycle is bottoming out, with volume recovery across major players and sequentially improved pricing, although spread recovery was delayed due to high raw material prices [3] - Wanhua Chemical is well-positioned for cyclical recovery, with a leading position in one of the most consolidated commodity chemical supply chains and long-term structural growth opportunities [8] - The company is expected to grow earnings at a +c 20% CAGR over 2023-26E, driven by new capacity projects for high-margin specialty chemicals and normalization of petrochemical earnings [6][8] Financial Estimates - 2024E-26E EPS estimates reduced by 5-9% to reflect weaker-than-expected margins in performance chemicals and new materials segment, higher opex, impairment losses, and finance expenses [2] - 2024E revenue estimate revised to Rmb198 310mn (from Rmb199 624mn), 2025E to Rmb228 460mn (from Rmb231 413mn), and 2026E to Rmb261 360mn (from Rmb262 856mn) [5] - 2024E net profit estimate revised to Rmb16 670mn (from Rmb18 227mn), 2025E to Rmb22 071mn (from Rmb24 199mn), and 2026E to Rmb26 748mn (from Rmb28 149mn) [5] Valuation and Catalysts - Target EV/EBITDA multiple slightly lowered to 10 5x (from 11 0x) to reflect reduced growth forecasts, but valuation base year rolled forward to average 2024E-25E [2] - Potential catalysts include US rate cuts and improving construction activities in Europe in early-mid 2025, which should support recovery in polyurethane demand and drive pricing/margin upside [2] - Strong pipeline of new capacity projects for high-margin specialty chemicals (e g , polyolefin elastomers and flavor and fragrance) scheduled to come on stream in 2H24 [3] Industry Position - Wanhua Chemical is the largest global producer of MDI (30% share of 2023 global capacity) and TDI (25% share of 2022 capacity) [6] - The company accounts for ~80% of global new polyurethane supply over 2023-25E, with continued volume share gains expected [6]

Investment Rating - The report indicates a soft core producer price inflation, leading to a revised estimate for the core PCE price index increase of 0.14% in July, down from 0.17% previously [2][3]. Core Insights - The producer price index (PPI) rose by 0.1% in July, which was below expectations, with core producer prices remaining unchanged. The PPI excluding food and energy was flat, while the PPI excluding food, energy, and trade services increased by 0.3% [2][3]. - Key components contributing to the PPI included a 0.6% increase in food prices and a 1.9% rise in energy prices. Retail margins saw a decline of 1.3% [2][3]. - The report highlights that the 'old methodology' core PPI for finished goods excluding food and energy increased by 0.1%, while core intermediate producer prices also rose by 0.1% [2]. Summary by Relevant Sections Producer Price Index (PPI) - PPI increased by 0.1% month-over-month for July, with a year-over-year increase of 2.2%. This was below Goldman Sachs' forecast of 0.2% [2]. - PPI excluding food and energy remained unchanged month-over-month, with a year-over-year increase of 2.4% [2]. - PPI excluding food, energy, and trade services increased by 0.3% month-over-month, with a year-over-year increase of 3.3% [2]. Core PCE Price Index - The core PCE price index is now estimated to have risen by 0.14% in July, a slight decrease from the previous estimate of 0.17% [3]. - The report suggests that further updates will follow the upcoming CPI report [3]. Key Numbers - PPI for July: +0.1% (month-over-month), +2.2% (year-over-year) [2]. - PPI excluding food and energy: flat (month-over-month), +2.4% (year-over-year) [2]. - PPI excluding food, energy, and trade services: +0.3% (month-over-month), +3.3% (year-over-year) [2].

Investment Rating - The report maintains a Neutral rating on UroGen Pharma (URGN) with a 12-month price target of $22, indicating a potential upside of 51.6% from the current price of $14.51 [42][43]. Core Insights - UroGen Pharma's Jelmyto sales remained flat year-over-year at $21.8 million, slightly below estimates, with challenges related to Medicaid/Medicare discounting impacting revenue guidance for FY24 [2][42]. - The company is focused on completing the rolling NDA submission for UGN-102, with expectations for priority review and potential commercialization in early 2025 [2][42]. - Management expressed confidence in the company's capitalization to reach profitability as it launches UGN-102 and advances its pipeline, despite caution regarding UGN-102's ability to replace TURBT surgery in the near term [2][42]. Financial Summary - UroGen Pharma reported total operating expenses of $184.9 million for 2Q24, slightly above expectations, driven by pre-commercial manufacturing costs for UGN-102 and increased R&D expenses for UGN-103 [2][42]. - The gross margin improved to 90.1%, while R&D expenses increased by 7.1% year-over-year [15][42]. - The company anticipates revenue growth, with projections of $95 million to $102 million for FY24, contingent on the uptake of Jelmyto and the successful launch of UGN-102 [2][42]. Model Adjustments - The report updates its model to reflect actuals from 2Q24 and adjusts near-term operating expense assumptions based on recent trends [2][42].

Investment Rating - The report maintains a "Buy" rating for UOL Group with a 12-month target price of S$7.75, slightly adjusted from the previous S$7.84 [2][12][13]. Core Insights - UOL reported a 1H24 core Patmi of S$143 million, reflecting an 8% year-over-year increase, but slightly below consensus estimates [2][3]. - Revenue decreased by 7% year-over-year to S$1.3 billion, primarily due to lower residential sales, although this was partially offset by increased investment and hotel revenue [2][3]. - The commercial portfolio showed strong rental reversions, and hotel RevPAR increased by 41% year-over-year, indicating a recovery in the hotel segment [2][7]. Financial Performance - The property development revenue was S$522 million, down 23% year-over-year, attributed to lower progressive recognition from Clavon and the absence of contributions from Avenue South Residence [4]. - The property investment revenue increased by 8% year-over-year to S$271 million, with a stable EBITDA margin of 32.1% [5][7]. - Hotel operations revenue rose by 11% year-over-year to S$378 million, with EBITDA increasing by 24% [7]. Strategic Initiatives - UOL is actively pursuing capital recycling, with the proposed divestment of Stamford Court at 21% above book valuation as part of its long-term portfolio optimization strategy [8][12]. - Upcoming project launches include Meyer Blue in September 2024 and additional sites in 2025 [4][8]. - The company is focusing on asset enhancement initiatives, with several projects expected to complete in the coming years [7]. Market Outlook - The report suggests that UOL's diversified portfolio across development and investment properties, hotels, and serviced suites positions it well for future growth [12]. - The valuation appears attractive, trading below -1 standard deviation discount to RNAV, indicating potential upside [12].